EHA 2011

 
 
 

16th Congress of the European Hematology Association

 

Highlights of poster presentations at EHA

Jon Wood Read Article
Published: 06/21/11

LONDON—The European Hematology Association (EHA) met here with an estimated 8,000 specialists from around the world. Over a thousand posters were presented; what follows is a sampling of some of the presentations. [Read Article]

ASCT the way to go with younger MM patients

Erilyn Riley Read Article
Published: 06/16/11

Palumbo_Antonio_EHA 2011.JPG
Antonio Palumbo, MD

The introduction of novel agents to treat multiple myeloma (MM) has called into question whether autologous stem cell transplant (ASCT) is really the best treatment strategy. Now, results of a phase 3 study shed some light on the role of ASCT in MM. Investigators found that ASCT confers a significant advantage in progression-free survival compared to conventional therapy containing novel agents. Antonio Palumbo, MD, from the University of Torino in Italy, presented the results at the 16th Congress of the European Hematology Association. [Read Article]

Rituximab maintenance doubles remission duration in MCL

Erilyn Riley Read Article
Published: 06/15/11

Kluin-Nelemans_Hanneke_EHA 2011.JPG
Hanneke Kluin-Nelemans, MD

New research has shown that rituximab maintenance doubles remission duration in patients with mantle cell lymphoma (MCL) compared to those on interferon-alfa (IFN) maintenance. Patients on rituximab experienced a median of 77 months remission duration compared to 24 months with IFN. Hanneke C. Kluin-Nelemans, MD, of the University Medical Center Groningen in The Netherlands, presented the results at the 16th Congress of the European Hematology Association held June 9 - 12. [Read Article]

Rapid symptom relief with new agent for MF

Erilyn Riley Read Article
Published: 06/14/11

Verstovsek-EHA 2011-1.jpg
Srdan Verstovsek, MD

The selective JAK1 and JAK2 inhibitor ruxolitinib rapidly decreases symptoms in myelofibrosis (MF) patients, according to results of the pivotal COMFORT-I study. Srdan Verstovsek, MD, from MD Anderson Cancer Center in Houston, Texas, reported the results recently at the annual meeting of the European Hematology Association. He reported the results of COMFORT-I earlier this month at ASCO. [Read Article]

Are patients really adhering to the drug regimen?

Erilyn Riley Read Article
Published: 06/13/11

Marin_David_EHA 2011.JPG
David Marin, MD

Expecting that his CML patients comply with treatment regimens, David Marin, MD, of Imperial College London, conducted a survey to determine their drug adherence levels. He was surprised by the results—in a 3-month period, only 40% of patients opened the medicine bottle everyday, and 13% failed to open the bottle more than a fifth of the days. He reported the results at a patient advocacy session held during the annual meeting of the European Hematology Association held June 9 – 12. [Read Article]

3 + 7 a terrible standard of care

Erilyn Riley Read Article
Published: 06/13/11

kantarjian-EHA 2011.jpg
Hagop Kantarjian, MD

A leading leukemia expert criticized the use of 3 + 7 as a standard of care in acute myeloid leukemia (AML) at a satellite symposium preceding the European Hematology Association (EHA) annual meeting. Saying that if we continue to use it we will never make any progress, Hagop Kantarjian, MD, discussed new salvage strategies for high-risk AML. The EHA annual meeting took place recently in London. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}